UA45762A - Спосіб лікування запальних гнійно-септичних захворювань жіночих статевих органів - Google Patents
Спосіб лікування запальних гнійно-септичних захворювань жіночих статевих органів Download PDFInfo
- Publication number
- UA45762A UA45762A UA2001064442A UA200164442A UA45762A UA 45762 A UA45762 A UA 45762A UA 2001064442 A UA2001064442 A UA 2001064442A UA 200164442 A UA200164442 A UA 200164442A UA 45762 A UA45762 A UA 45762A
- Authority
- UA
- Ukraine
- Prior art keywords
- blood
- purulent
- treatment
- autotransfusion
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 238000011282 treatment Methods 0.000 title claims description 33
- 201000010099 disease Diseases 0.000 title claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 17
- 230000002757 inflammatory effect Effects 0.000 title claims description 17
- 210000004392 genitalia Anatomy 0.000 title description 5
- 210000004369 blood Anatomy 0.000 claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 37
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 24
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 11
- 238000012937 correction Methods 0.000 claims abstract description 10
- 238000001784 detoxification Methods 0.000 claims abstract description 9
- 230000004089 microcirculation Effects 0.000 claims abstract description 8
- 230000037396 body weight Effects 0.000 claims description 11
- 210000001752 female genitalia Anatomy 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000003792 electrolyte Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 2
- 238000012876 topography Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 abstract description 8
- 230000022558 protein metabolic process Effects 0.000 abstract description 3
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 102000003390 tumor necrosis factor Human genes 0.000 description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 5
- 229930182566 Gentamicin Natural products 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 229960002518 gentamicin Drugs 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 208000004145 Endometritis Diseases 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 108010040201 Polymyxins Proteins 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010016855 Foetal distress syndrome Diseases 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 2
- 206010048714 Gastroduodenitis Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010040102 Seroma Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 208000017983 photosensitivity disease Diseases 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000004911 serous fluid Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940046284 zinacef Drugs 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- -1 IL-A4 Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229940087211 ciprofloxacin and metronidazole Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000000023 hypocoagulative effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000011460 mild pre-eclampsia Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 231100001258 radiotoxin Toxicity 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000005608 severe pre-eclampsia Diseases 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000003195 tocolytic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Landscapes
- Apparatus For Disinfection Or Sterilisation (AREA)
Abstract
Способ лечения воспалительных гнойно-септических заболеваний женских половых органов включает в себя аутотрансфузию экстракорпорально облученной крови, антибактериальную, инфузионно-трансфузионную терапию, коррекцию микроциркуляции, белкового, водно-электролитного обмена и кислотно-щелочного равновесия. Для облучения отбирают порцию венозной крови в объеме 3-5 мл на 1 кг массы тела пациентки, облучают ее рентгеновскими лучами при интегральной поглощенной дозе 250-300 Гр. Потом проводят 1-2 аутотрансфузии облученной крови. Аутотрансфузию проводят в первый день после санации гнойного очага, перерыв между двумя аутотрансфузиями составляет 2-3 дня.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2001064442A UA45762A (uk) | 2001-06-25 | 2001-06-25 | Спосіб лікування запальних гнійно-септичних захворювань жіночих статевих органів |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2001064442A UA45762A (uk) | 2001-06-25 | 2001-06-25 | Спосіб лікування запальних гнійно-септичних захворювань жіночих статевих органів |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA45762A true UA45762A (uk) | 2002-04-15 |
Family
ID=74206615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001064442A UA45762A (uk) | 2001-06-25 | 2001-06-25 | Спосіб лікування запальних гнійно-септичних захворювань жіночих статевих органів |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA45762A (ru) |
-
2001
- 2001-06-25 UA UA2001064442A patent/UA45762A/uk unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2309744C1 (ru) | Способ лечения послеродового эндометрита | |
| Thakur et al. | Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate. | |
| UA45762A (uk) | Спосіб лікування запальних гнійно-септичних захворювань жіночих статевих органів | |
| MELENEY | SEASONAL INCIDENCE OF HEMOLYTIC STREPTOCOCCUS IN THE NOSE AND THROAT: IN A SURGICAL OPERATING PERSONNEL; SIGNIFICANCE OF MASKING DURING OPERATION | |
| Hoback et al. | Treatment of snake venom poisoning with cortisone and corticotropin | |
| Haase et al. | Clinical evaluation of rosoxacin for the treatment of chancroid | |
| RU2771856C1 (ru) | Способ лечения неосложненного некротизирующего энтероколита у новорожденных с бактериальной инфекцией и при подозрении на наличие внутриутробной инфекции | |
| RU2142821C1 (ru) | Способ лечения острых воспалительных заболеваний внутренних половых органов у женщин | |
| RU2585097C1 (ru) | Способ лечения хронического панкреатита | |
| RU2820554C1 (ru) | Способ лечения гнойно-воспалительных заболеваний придатков матки | |
| RU2153892C2 (ru) | Способ лечения хронических воспалительных заболеваний внутренних половых органов у женщин | |
| Cohen et al. | Mebaral in the treatment of epilepsy | |
| RU2238096C1 (ru) | Способ лечения аутоиммунного бесплодия у мужчин | |
| RU2370263C2 (ru) | Способ детоксикации организма в хирургии инвазивного рака мочевого пузыря | |
| RU2145891C1 (ru) | Способ комплексной терапии больных хроническим аднекситом, инфекционно-токсический вариант, неспецифической этиологии | |
| RU2154477C1 (ru) | Способ лечения хронического трихомониаза | |
| Walker et al. | Necrotizing fasciitis: the Howard university hospital experience | |
| Colebrook | Some laboratory investigations in connexion with puerperal fever | |
| UA52539A (ru) | Способ лечения гнойно-воспалительных заболеваний у рожениц в послеродовом периоде | |
| DOWNS | A REACTION TO DRIED POOLED HUMAN PLASMA¹ | |
| RU2546039C1 (ru) | Способ лечения больных осложненных формами рожистого воспаления | |
| RU2155037C1 (ru) | Способ лечения хронического урогенитального кандидоза у женщин | |
| UA145586U (uk) | Спосіб антибактеріальної терапії сепсису | |
| UA75078U (ru) | Способ консервативного лечения хронического простатита, осложненного конкрементами в предстательной железе | |
| RU2180567C1 (ru) | Способ лечения хронического рецидивирующего трихомониаза |